These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25050065)

  • 1. Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
    Konya H; Yano Y; Matsutani S; Tsunoda T; Ikawa T; Kusunoki Y; Matsuo T; Miuchi M; Katsuno T; Hamaguchi T; Miyagawa J; Namba M
    Ther Clin Risk Manag; 2014; 10():547-58. PubMed ID: 25050065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.
    Kulasa K; Edelman S
    Core Evid; 2010 Oct; 5():23-37. PubMed ID: 21042540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
    Cobble ME; Frederich R
    Cardiovasc Diabetol; 2012 Jan; 11():6. PubMed ID: 22248301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical overview of saxagliptin for Type 2 diabetes management.
    Rosenstock J
    Expert Rev Endocrinol Metab; 2010 Nov; 5(6):809-823. PubMed ID: 30780831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
    Gallwitz B
    Diabetes Metab Syndr Obes; 2010 May; 3():117-24. PubMed ID: 21437082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saxagliptin for type 2 diabetes.
    Chacra AR
    Diabetes Metab Syndr Obes; 2010 Sep; 3():325-35. PubMed ID: 21437102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
    Schwartz SL
    Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Price DL; Chen R; Udell J; Raz I
    Am Heart J; 2011 Nov; 162(5):818-825.e6. PubMed ID: 22093196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.
    Dave DJ
    J Pharmacol Pharmacother; 2011 Oct; 2(4):230-5. PubMed ID: 22025849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.
    Sharma MD
    Ther Clin Risk Manag; 2010 May; 6():233-7. PubMed ID: 20526441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin in type 2 diabetes.
    Billiones R
    Drugs Today (Barc); 2010 Feb; 46(2):101-8. PubMed ID: 20393638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
    Santamarina M; Carlson CJ
    BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
    N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.